Target-based drug discovery is not entirely new for malaria, and several antimalarial drug candidates that were identified this way have progressed to human trials, including molecules that target dihydroorotate dehydrogenase (DHODH) and dihydrofolate reductase (DHFR) [20–22]. The gene discussed is DHODH; the disease is malaria.